VolitionRx’s Capture-Seq™ Achieves Over 99% Pure Tumor DNA, Eyes $36B Market
VolitionRx’s Capture-Seq™ technology isolates over 99% pure circulating tumor DNA using a two-step physical enrichment and bioinformatic method. The company targets a $36 billion multi-cancer early detection and MRD market and is in talks with global diagnostic leaders for commercialization.
1. Capture-Seq™ Technology Breakthrough
VolitionRx’s novel Capture-Seq™ method physically enriches and bioinformatically removes non-tumor cfDNA to isolate over 99% pure circulating tumor-derived DNA, marking a world-first in liquid biopsy assay development. The two-step process combines CTCF-bound DNA capture with advanced sequencing to generate high-purity ctDNA datasets.
2. Clinical Validation Results
Early blinded validation across two independent cohorts reported zero false positives, detecting all 49 cancers (including 23 early-stage I/II) in the first group and 13 of 14 in a later-stage cohort with controls. Further validation on additional early-stage samples is underway to confirm sensitivity and specificity.
3. Market Opportunity
The company estimates a total addressable market of $36 billion, comprising approximately $23 billion for multi-cancer early detection and $13 billion for minimal residual disease monitoring. This expansive opportunity positions the technology for significant commercial impact in oncology diagnostics.
4. Commercialization and Partnerships
VolitionRx is in active discussions with multiple global diagnostic and liquid biopsy companies to accelerate Capture-Seq™ commercialization. The company anticipates licensing agreements for human and veterinary applications to leverage broad demand for early detection and disease monitoring solutions.